Description: <p><b>Anethole</b> — Anethole is a naturally occurring aromatic phenylpropene and volatile essential-oil constituent best represented by <i>trans</i>-anethole, the dominant anise-like compound in anise, star anise, fennel, and related botanicals. It is formally a small-molecule natural product / flavoring-agent phytochemical rather than an approved oncology drug. Standard abbreviations include ANE, t-ANE, and tAT for <i>trans</i>-anethole. In cancer research it is best classified as a preclinical multi-pathway chemosensitizing phytochemical with stronger evidence for apoptosis, cell-cycle arrest, NF-κB/PI3K-AKT/STAT3 modulation, and context-dependent oxidative-stress effects than for direct clinical use.<br>
-botanical sources can co-contain estragole, especially fennel/basil/tarragon-type materials. Estragole is a separate phenylpropene with stronger toxicology concern, so whole-herb or essential-oil entries should not be treated as pure anethole<br>
anethole analogues eugenol and isoeugenol
</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of intrinsic apoptosis through mitochondrial membrane-potential disruption, Bax/Bcl-2-family shift, caspase-9/caspase-3 activation, and DNA-fragmentation phenotypes.</li>
<li>Suppression of proliferative and survival signaling, especially PI3K/AKT, STAT3, NF-κB, AP-1, JNK, and MAPK-related inflammatory-survival axes.</li>
<li>Cell-cycle arrest and anti-clonogenic effects in several cancer-cell models, including prostate, breast, oral, osteosarcoma, lung, and glioma models.</li>
<li>Autophagy modulation, especially in oral-cancer models, where anethole has been reported to trigger autophagy alongside apoptosis.</li>
<li>Oxidative-stress modulation, which is model-dependent: some cancer models show ROS increase and mitochondrial stress, while oral-cancer data report ROS decrease with increased GSH activity.</li>
<li>Chemosensitization, most clearly preclinical synergy with cisplatin in oral-cancer cells.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Anethole is lipophilic and orally absorbable, with human metabolic studies showing dose-dependent disposition and major urinary detoxication products such as 4-methoxyhippuric acid. Translation is constrained by rapid metabolism, flavor-level safety limits, and the fact that many anticancer experiments use concentrations unlikely to be achieved safely through dietary exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer effects are concentration-driven and commonly occur in the tens to hundreds of micromolar range. These levels likely exceed normal dietary or flavoring exposure and should be treated as pharmacologic experimental exposure rather than food-use exposure.</p>
<p><b>Clinical evidence status:</b> Preclinical. There is no established human oncology indication for anethole and no convincing registered cancer trial program for anethole as an anticancer therapy. Evidence is mainly cell-culture, limited animal xenograft, and combination/sensitization studies.</p>
<h3>Anethole Cancer Mechanism Table</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mitochondrial apoptosis</td>
<td>↑ Bax, ↑ caspase-9, ↑ caspase-3, ↓ ΔΨm, ↑ apoptosis</td>
<td>Likely lower cytotoxicity at food-level exposure</td>
<td>R/G</td>
<td>Pro-apoptotic tumor-cell killing</td>
<td>Core anticancer mechanism across multiple preclinical models; strongest translational signal is apoptosis rather than selective clinical cytotoxicity.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K AKT survival signaling</td>
<td>↓ AKT pathway signaling, ↓ proliferation, ↑ apoptosis</td>
<td>Not well defined</td>
<td>G</td>
<td>Survival-pathway suppression</td>
<td>Reported in breast, lung, glioma, and other cancer models; pathway centrality is high but clinical validation is absent.</td>
</tr>
<tr>
<td>3</td>
<td>STAT3 survival signaling</td>
<td>↓ STAT3 signaling, ↓ proliferation, ↑ apoptosis</td>
<td>Not well defined</td>
<td>G</td>
<td>Anti-proliferative and pro-apoptotic signaling shift</td>
<td>Most relevant where STAT3 is constitutively active or coupled to inflammatory survival signaling.</td>
</tr>
<tr>
<td>4</td>
<td>NF-κB AP-1 JNK MAPK inflammatory signaling</td>
<td>↓ TNF-induced NF-κB, ↓ AP-1, ↓ JNK, ↓ MAPK kinase signaling</td>
<td>↓ inflammatory signaling may be cytoprotective or anti-inflammatory</td>
<td>P/R</td>
<td>Anti-inflammatory survival-axis suppression</td>
<td>Mechanistically important for inflammation-linked carcinogenesis, but TNF-apoptosis blockade means the biological direction can be context-dependent.</td>
</tr>
<tr>
<td>5</td>
<td>Cell cycle and clonogenic growth</td>
<td>↓ proliferation, ↓ colony formation, ↑ G0/G1 arrest or model-specific arrest</td>
<td>Not well defined</td>
<td>G</td>
<td>Growth suppression</td>
<td>Observed in prostate, osteosarcoma, breast, lung, and oral-cancer models; generally requires pharmacologic exposure.</td>
</tr>
<tr>
<td>6</td>
<td>Autophagy modulation</td>
<td>↑ autophagy markers in oral-cancer models</td>
<td>Not well defined</td>
<td>R/G</td>
<td>Stress-response remodeling</td>
<td>May contribute to cell death or adaptive stress response depending on tumor context and dose.</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial ROS increase</td>
<td>↑ ROS in osteosarcoma and some apoptosis models</td>
<td>At low exposure may show antioxidant behavior</td>
<td>R/G</td>
<td>Oxidative mitochondrial stress</td>
<td>Not uniform across studies; oral-cancer data also report ↓ ROS and ↑ GSH, so ROS should be marked model-dependent rather than universally pro-oxidant.</td>
</tr>
<tr>
<td>8</td>
<td>GSH antioxidant buffering</td>
<td>↑ GSH in oral-cancer model, with apoptosis and autophagy</td>
<td>Potential antioxidant effect</td>
<td>R/G</td>
<td>Redox-state modulation</td>
<td>May reflect compensatory antioxidant response rather than the primary cytotoxic driver.</td>
</tr>
<tr>
<td>9</td>
<td>Chemosensitization to cisplatin</td>
<td>↑ cisplatin cytotoxicity, ↑ apoptosis, ↑ anti-tumor signaling effects</td>
<td>Normal-cell protection not established</td>
<td>G</td>
<td>Adjunct sensitization</td>
<td>Promising but preclinical; no dosing or safety framework for oncology combination use.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>In-vitro activity often requires high concentration</td>
<td>Food/flavoring exposure is safety-limited</td>
<td>G</td>
<td>Exposure and safety bottleneck</td>
<td>GRAS/flavoring status does not imply anticancer-dose safety; metabolism, hepatotoxicity/genotoxic-metabolite concerns, and estragole contamination in botanicals are key constraints.</td>
</tr>
</tbody>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>